---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-054712"
form_type: "8-K"
ticker: null
cik: "0000786947"
company_name: "ACURA PHARMACEUTICALS, INC"
filed_at: "2025-05-30T23:59:59+00:00"
generated_at: "2026-05-20T05:14:22.663231+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Acura extends debt maturity and LTX-03 NDA deadline to Dec 31, 2025; warns of cash crunch

## Summary
- Principal balance on AD Pharma promissory note $7,994,279 plus ~$683,000 accrued interest as of May 29, 2025.
- Maturity of note extended from May 31, 2025 to December 31, 2025.
- FDA NDA acceptance deadline for LTX-03 (hydrocodone/APAP) extended from May 31, 2025 to December 31, 2025 per Amendment #12.
- Warrant to purchase 10M shares at $0.01 also extended to expire Dec 31, 2025.
- Company states without additional financing by mid-June 2025 it will shut down or seek bankruptcy, risking total loss of shareholder value.

## SEC filing metadata
- accession: 0001104659-25-054712
- form_type: 8-K
- cik: 0000786947
- company_name: ACURA PHARMACEUTICALS, INC
- filed_at: 2025-05-30T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/786947/000110465925054712/0001104659-25-054712-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/786947/000110465925054712/tm2516608d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-054712
- JSON: https://secwatch.observer/filing/0001104659-25-054712.json
- Plain text: https://secwatch.observer/filing/0001104659-25-054712.txt

## Key facts
- Debt Financings
  ACURA PHARMACEUTICALS, INC amended debt with Abuse Deterrent Pharma, LLC maturing December 31, 2025.
  - Counterparty: Abuse Deterrent Pharma, LLC
  - Maturity: December 31, 2025
  - Event: amendment
  source text: This amendment #6 has an effective date of May 29, 2025 and changes the maturity date of the Amended Note from May 31, 2025 to December 31, 2025, at which time all principal and interest is due.
  evidence_url: https://www.sec.gov/Archives/edgar/data/786947/000110465925054712/0001104659-25-054712-index.htm
- Debt Financings
  ACURA PHARMACEUTICALS, INC incurred loan of $100,000 loans with Abuse Deterrent Pharma, LLC at 5.25%.
  - Instrument: loan
  - Principal: $100,000 loans
  - Counterparty: Abuse Deterrent Pharma, LLC
  - Rate: 5.25%
  - Event: incurrence
  source text: On both May 2, 2025 and May 22, 2025, we received $100,000 loans from Abuse Deterrent Pharma, LLC (“AD Pharma”). These loans combined with previous loans made to the Company and combined with the $2,319,279 under the November 10, 2022 Amended Consolidated and Restated Secured Promissory Note, now has a principal balance of $7,994,279 with accrued interest of approximately $683,000 as of May 29, 2025 and bears interest at 5.25% (“Note”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/786947/000110465925054712/0001104659-25-054712-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.